
Index

A

- Acupuncture, complementary therapies, 271
- Adenosine triphosphate (ATP), 67
- Aging
 - anemia pathogenesis, 257
 - clinical evaluation
 - comprehensive geriatric assessment (CGA), 252–255
 - frailty index, 252–254
 - mortality rate, 251
- Anemia, erythropoietic drug
 - cancer patient survival, 159
 - chemotherapy, 154, 156
 - epoetin alfa and darbepoetin alfa, 158, 159
 - erythropoietic drug
 - adverse events associated with, 158
 - recommended doses and regimens, 156–157
 - target hemoglobin, 156
 - treatment initiation and dose modification, 157
 - initial laboratory evaluation, 154
 - iron dextran, 160
 - mechanisms of, 154, 155
 - monitoring of iron stores, 158
 - older cancer patient, 256–257
 - parenteral iron therapy, 160, 161
 - treatment options for, 155, 156
- Anorexia
 - alimentary tract dysfunction, 53
 - categories, 48
 - causes, 49
 - cytokines, 49, 54–55
 - glucose utilization and futile substrate cycles, 53–54
 - hormonal aberration, 58–59
 - multifactorial, 49
 - neuropeptidergic circuits dysregulation, 50–53, 59
 - pharmacologic management
 - anabolic androgenic steroids, 61
 - anti-inflammatory cytokines, 67–68
 - ATP, 67
 - branched-chain amino acids, 71–72
 - cannabinoids, 62
 - clenbuterol, 66
 - corticosteroids, 60
 - cyproheptadine, 73
 - cytokine inhibitors and antibodies, 67–68
 - 5'-dFUrd, 67
 - EPA, 69
 - GHRH (GHRP-2), 62–63

- growth hormone (GH), 62–63
 - HMB, 70
 - hydrazine sulfate, 64
 - IGF-1, 63–64
 - indomethacin, ibuprofen, and celecoxib, 64–65
 - L-arginine/L-glutamine, 70
 - megestrol acetate and medroxyprogesterone acetate, 61
 - melatonin, 72
 - metoclopramide and cisapride, 64
 - nutrition, 70–71
 - orexigenic and anorexigenic mediators, 72
 - pentoxifylline and lisofylline, 65
 - proteasome and NF-kB inhibitors, 65–66
 - somatostatin, 62–63
 - thalidomide, 66–67
 - prostaglandin elevation, 59
 - serotonin, 49
 - signal transduction pathway, 57–58
 - supportive care, 60
 - tumor byproducts, 56–57
 - tumor parasitism, 59
- Antidepressants, 145–147
- Antiemetics
 - corticosteroids, 186
 - dopamine receptor antagonists, 185–186
 - 5-HT₃ receptor antagonists, 182–185
 - neurokinin-1 (NK-1) receptors, 186–187
- ATP. *See* Adenosine triphosphate

B

- Bupropion, 148

C

- Cachexia
 - anorexia
 - alimentary tract dysfunction, 53
 - categories, 48
 - causes, 49
 - cytokines, 49, 54–55
 - glucose utilization and futile substrate cycles, 53–54
 - hormonal aberration, 58–59
 - multifactorial, 49
 - neuropeptidergic circuits dysregulation, 50–53, 59
 - prostaglandin elevation, 59

- Cachexia (*continued*)
- serotonin, 49
 - signal transduction pathway, 57–58
 - tumor byproducts, 56–57
 - tumor parasitism, 59
- complex syndrome, 48
- etiology and mechanisms, 48–59
- pharmacologic management
- anabolic androgenic steroids, 61
 - anti-inflammatory cytokines, 67–68
 - ATP, 67
 - branched-chain amino acids, 71–72
 - cannabinoids, 62
 - clenbuterol, 66
 - corticosteroids, 60
 - cyproheptadine, 73
 - cytokine inhibitors and antibodies, 67–68
 - 5'-dFUrD, 67
 - EPA, 69
 - GHRH (GHRP-2), 62–63
 - growth hormone (GH), 62–63
 - HMB, 70
 - hydrazine sulfate, 64
 - IGF-1, 63–64
 - indomethacin, ibuprofen, and celecoxib, 64–65
 - L-arginine/L-glutamine, 70
 - megestrol acetate and medroxyprogesterone acetate, 61
 - melatonin, 72
 - metoclopramide and cisapride, 64
 - nutrition, 70–71
 - orexigenic and anorexigenic mediators, 72
 - pentoxifylline and lisofylline, 65
 - proteasome and NF- κ B inhibitors, 65–66
 - somatostatin, 62–63
 - thalidomide, 66–67
- supportive care, 60
- Cancer pain
- celiac plexus neurolysis, 40
 - evaluation
 - Memorial Pain Assessment Card, 36
 - severity, 36
 - visual analogue scale (VAS), 35–36
 - Wisconsin Brief Pain Inventory, 35
 - long-acting local anesthetics, 39
 - neurostimulatory techniques, 39
 - optimal analgesia, 34–35
 - pharmacologic management
 - adjuvant analgesics, 38
 - classification, 36
 - opioids, 37, 38
 - radiation therapy, 39
 - systemic radiopharmaceuticals and chemotherapy, 39
 - problems
 - cognitive or communicative function, 40–41
 - drug abuse, 42–43
 - episodic or incident pain, 41–42
 - neuropathic pain, 42
- Cancer-related fatigue
- CFS, 88
- complexity
- case definitions, 93
 - conceptual model, 91–92
 - four filters, 90
 - limitations, 93–95
 - NCCN, 89
 - patient vignettes, 91
 - practice guidelines, 89
- etiology, 95–98
- predisposing and perpetuating factors, 98
- therapy
- acute/subacute infection, 100
 - anemia, 99–100
 - antidepressants, 102–103
 - behavioral and psychoeducational interventions, 102
 - CCOP, 98, 99
 - exercise program, 100–101
 - good nutrition, 101–102
 - metabolic disorders, 100
 - mind/body interventions, 101
 - psychostimulants, 103
 - specific therapy, 100
- Cardiotoxicity, older cancer patients, 259
- Central venous catheters (CVC), 114
- Chemotherapy-induced emesis
- distinct types, 181
 - prevention and treatment
 - antiemetic prophylaxis, 189
 - cisplatin and cyclophosphamide, 189
 - guidelines, 188
 - 5-HT₃ receptor antagonist and dexamethasone combination, 189
- Chemotherapy-induced nausea and vomiting (CINV)
- anticipatory, 190
 - antiemetics
 - corticosteroids, 186
 - dopamine receptor antagonists, 185–186
 - 5-HT₃ receptor antagonists, 182–185
 - neurokinin-1 (NK-1) receptors, 186–187
 - breakthrough symptoms, 189–190
 - emesis, 181, 188–189
 - pathophysiology, 180–181
 - prevention and control, 181–182
 - RINV, 190
- Chemotherapy-induced neutropenia
- management strategy

- dose reduction delay, 167–168
 - myeloid growth factors, 170–173
 - practice guidelines, 174–176
 - prophylactic antibiotics, 168–170
 - morbidity and mortality, 166
 - Chronic fatigue syndrome (CFS), 88, 95
 - Ciliary neurotrophic factor, 54
 - CINV. *See* Chemotherapy-induced nausea and vomiting
 - CNTF. *See* Ciliary neurotrophic factor
 - Cognitive-behavioral therapy, 149
 - Complementary and alternative medicine (CAM), 269, 270
 - Complementary therapies, cancer care
 - acupuncture, 271
 - herbal supplements, 275
 - massage therapy, 272
 - mind-body therapies, 273–274
 - music therapy, 272–273
 - Comprehensive geriatric assessment (CGA)
 - cardiovascular health study (CHS) assessment, 252, 255
 - cytotoxic chemotherapy, algorithm for, 254
 - frailty index, 252–254
 - Computed tomography (CT), 22
 - Constipation
 - assessment, 222
 - causes, 221
 - etiology, 219–222
 - management, 222–224
 - Cytokine hypothesis
 - central nervous system, 96
 - interferon-alpha (IFN- α), 96
 - model, 97
 - receptors, 96
 - serotonin reuptake inhibitor paroxetine, 98
 - sickness behavior, 95, 96
- D**
- Darbepoetin alfa, 156, 158, 159
 - Deep venous thrombosis (DVT)
 - and central venous catheters (CVC), 114
 - post-thrombotic syndrome, 127
 - Delirium, older cancer patients, 263
 - Delta 9-tetrahydrocannabinol, 62
 - 5'-Deoxy-5-Fluorouridine (5'-dFUrd), 67
 - Depression
 - antidepressant medications, 145, 146
 - complications, 143
 - comprehensive approach management, 145
 - evaluation and diagnosis
 - conceptual approaches, 140, 141
 - depressive symptoms assessment, 140
 - DSM-IV subcategories, 141, 142
 - monoamine oxidase inhibitors (MAOIs), 147
 - newer antidepressants, 148–149
 - prevalence, 140
 - psychostimulants and wakefulness-promoting agents, 148, 149
 - psychotherapy and ECT, 149
 - risk factors, 142, 143
 - SSRIs and tricyclic antidepressants, 146, 147
 - suicide assessment and management, 144–145
 - DEXA. *See* Dual isotope X-ray absorption
 - DexFerrum®, 160
 - Diarrhea
 - causes, 215
 - classification, 214
 - definition, 213
 - general treatment
 - citrucel, 217
 - codeine and loperamide, 219
 - prostaglandin inhibitors, 219
 - somatostatin analogues, 219
 - treatment-induced
 - algorithm, 218
 - carcinoid syndrome, 216–217
 - clostridium difficile colitis, 217
 - irinotecan and fluorouracil, 214
 - typical symptoms, 214
 - Dronabinol. *See* Delta 9-tetrahydrocannabinol
 - Dual isotope X-ray absorption (DEXA), 232
 - Duloxetine, 148
 - Dyspnea
 - causes, 6
 - definition, 1
 - etiologies, 5–6
 - nonpharmacologic therapies
 - cognitive/behavioral interventions, 10–11
 - integrative therapies, 11
 - NIPPV, 11
 - pathophysiology
 - breathing effort, 2–3
 - chemoreception, 2
 - clinical causes, 4
 - cortical activity and perception, 4–5
 - language, 4
 - neuromechanical dissociation, 3
 - refractory, 11–12
 - symptomatic management
 - anxiolytics, 7
 - furosemide, 10
 - lidocaine, 10
 - opioids, 8–10
 - oxygen, 6–7
- E**
- Ecythcipoiesis-stimulatory agents, 115
 - Eicosapentaenoic acid (EPA), 69
 - Electroconvulsive therapy (ECT), 149
 - Emetogenic chemotherapy, 182, 189

End-of-life decision making
 autonomy paradigm drawbacks, 284–285
 communication, 281–283, 286
 deficits research, 281–283
 evidence-based approach
 history-taking skills and differential
 diagnosis, 286
 planning over time and systematic
 approach, 285
 hospice care, 280
 interventions and improved ratings of, 283–284
 palliative care, 281, 283, 284
 Epoetin alfa, 156, 158, 159
 Erythropoietic drug, anemia
 adverse events, 158
 recommended doses and regimens, 156–157
 target hemoglobin, 156
 treatment initiation and dose modification, 157
 Erythropoietic stimulating factors (ESF), 258
 Erythropoietin, 115
 ESA. *See* Ecythcopoiesis-stimulatory agents

F

Ferrlecit®, 160
 Fluorodeoxyglucose (FDG), 23
 5-Fluorouracil, 113
 Fondaparinux, 121, 124
 Functional Assessment of Cancer Therapy
 (FACT), 103

G

Gastrointestinal malignancy
 constipation
 assessment, 222
 causes, 221
 etiology, 219–222
 management, 222–224
 diarrhea
 causes, 215
 classification, 214
 definition, 213
 general treatment, 217–219
 treatment-induced, 214–217
 typical symptoms, 214
 GH-releasing hormone (GHRH), 63
 Granulocyte monocyte colony-stimulating factor
 (GM-CSF), 170–172
 Growth hormone (GH), 62–63

H

Hematopoietic stem cell transplants (HSCT), 199
 Heparin-induced thrombocytopenia (HIT), 121,
 128
 b-Hydroxy-b-methylbutyrate (HMB), 70
 Hypnosis, 273, 274

I

Imferon®, 160
 InFed®, 160
 Insulin-like growth factor–1 (IGF–1), 63–64
 Interleukin–1 (IL–1), 49

K

Keratinocyte growth factor (KGF), 258

L

L-Asparaginase, 113
 Leukemia inhibitory factor (LIF), 54, 56
 Low molecular weight heparin (LMWH)
 chronic therapy, 124
 heparin-induced thrombocytopenia (HIT), 121
 and warfarin, 126

M

Magnetic resonance imaging (MRI), 22
 Menopausal symptoms
 definition, 228
 hot flashes and night sweats
 complementary therapies and dietary
 supplements, 232
 definition and natural course, 229
 hormonal therapies, 230–231
 nonhormonal treatments, 230–232
 pathophysiology, 229
 prevalence, 229
 insomnia
 benzodiazepines, 240
 complementary therapies and dietary
 supplements, 241
 definition and natural course, 239
 nonbenzodiazepine hypnotics, 240–241
 pathophysiology, 239–240
 prevalence, 239
 sleep hygiene strategy, 240
 osteoporosis
 bisphosphonates, 234–235
 calcitonin, 235
 definition and natural course, 232–233
 dietary supplements, herbs, and complemen-
 tary therapies, 236–237
 hormone replacement therapy, 234
 pathophysiology, 233
 physical exercise, 236
 prevalence, 233
 raloxifene, 235
 teriparatide, 235–236
 vaginal dryness and dyspareunia
 complementary therapies and dietary
 supplements, 239
 definition and natural course, 237
 pathophysiology, 237

- prevalence, 237
 - sexual activity maintenance, 239
 - vaginal estrogen, 238
 - vaginal lubricants and moisturizers, 238–239
 - Mirtazapine, 148
 - Monoamine oxidase inhibitors (MAOIs), 147
 - MRI. *See* Magnetic resonance imaging
 - Mucositis, older cancer patients, 258–259
 - Myeloid growth factors
 - FDA-approved indications, 171
 - G-CSF and GM-CSF, 170–172
 - practice guidelines, 173–174
- N**
- National cancer institute common toxicity criteria (NCI-CTC), 197
 - National Comprehensive Cancer Network (NCCN), 89, 98
 - Nefazodone, 148
 - Neurokinin-1 (NK-1) receptors, 186–187
 - Neurotoxicity, older cancer patients, 259
 - Neutropenia
 - chemotherapy-induced
 - dose reduction delay, 167–168
 - myeloid growth factors, 170–173
 - practice guidelines, 174–176
 - prophylactic antibiotics, 168–170
 - dose-limiting toxicity, 165
 - economic impact, 167
 - fever and infection, 166
 - oncologic emergency, 166
 - Neutropenia, older cancer patients, 255–256
 - Noninvasive positive pressure ventilation (NIPPV), 11
- O**
- Older cancer patients, supportive care
 - aging
 - biology of, 250–251
 - clinical evaluation, 251–255
 - caregiver role, 264
 - chemotherapy complications
 - anemia, 256–258
 - cardiotoxicity and neurotoxicity, 259
 - mucositis, 258–259
 - NCCN guidelines, 260
 - neutropenia and and neutropenic infections, 255–256
 - delirium, 263
 - hormonal therapy complications
 - adjuvant hormonal treatment, 261
 - androgen deprivation, 260
 - malnutrition, 263–264
 - pain management
 - features of, 261–263
 - pain assessment, 262
 - OMAS. *See* Oral Mucositis Assessment Scale
 - OMI. *See* Oral Mucositis Index
 - Opioids, 262
 - classification, 37–38
 - important principles, 38
 - Oral mucositis
 - assessment and scoring
 - functional categories, 196
 - NCI-CTC and WHO scales, 197, 198
 - nursing management scales, 198
 - OMAS and OMI scales, 198
 - clinical features
 - opioid analgesics and diet modification, 194
 - radiation-induced, 195, 196
 - throat pain and dysphagia, 195
 - epidemiology
 - genetic makeup, 200
 - HSCT, 199
 - treatment-related toxicity *vs.* study endpoint, 199
 - health and economic impact, 200
 - pathophysiology
 - healing, 204
 - initiation, 203
 - primary damage response, 203–204
 - signal amplification, 204
 - ulceration, 204
 - prevention and treatment
 - biologically based, 207
 - intensity modulated radiation therapy (IMRT), 208
 - recognition, 209
 - Oral Mucositis Assessment Scale (OMAS), 198
 - Oral Mucositis Index (OMI), 198
 - Osteoporosis, 260
- P**
- Pegylated liposomal doxorubicin (PLD), 259
 - Peripherally inserted central catheters (PICC), 114
 - Positron emission tomography (PET), 23
 - Post-thrombotic syndrome, 127
 - Psychotherapy, 149
- R**
- Radiation-induced nausea and vomiting (RINV), 190
 - Rhenium-188, 28
- S**
- Samarium-153, 28
 - Selective serotonin reuptake inhibitors, 147

- Skeletal metastases
 economic impact, 20–21
 imaging
 bone scintigraphy, 22
 CT, 22
 MRI, 22
 PET, 23
 plain film radiography, 21–22
 morbidity, 18
 pathophysiology
 metastasis pattern, 18
 osteoclasts and osteoblasts, 18–19
 presentation and complications, 20
 treatment
 biochemical markers for bone turnover, 29
 bisphosphonates, 24–26
 chemotherapy and hormonal therapy, 23–24
 radiation, 26–27
 radionuclides, 27–28
 surgery, 28–29
- SSRIs. *See* Selective serotonin reuptake inhibitors
- Strontium–89, 28
- T**
- Thalidomide, 114
- Thrombomodulin, 112
- Tissue plasminogen activator (tPA), 123
- Trazodone, 148
- Tricyclic antidepressants, 147
- Trousseau's syndrome, 128, 129
- Tumor byproducts
 lipolytic factors, 56–57
 proteolysis-inducing factor (PIF), 57
- Tumor necrosis factor- α (TNF- α), 49
- U**
- Unfractionated heparin (UFH), 120, 124, 125
- V**
- VAS. *See* Visual analogue scale
- Venlafaxine, 148
- Venofor®, 160
- Venous thromboembolism (VTE)
 anticoagulation impact, 129–130
 central venous catheter thrombosis prevention,
 118–119
 chronic therapy
 LMWH and warfarin, 126
 post-thrombotic syndrome, 127
 VKA role, 124, 125
 diagnosis, 119–120
 epidemiology, 110–111
 initial therapy
 catheter thrombosis, 124
 contraindications, outpatient treatment, 121, 122
 LMWH and UFH, 121
 PE risk score, 122
 thrombolytic therapy, 123
 treatment regimens, 120
 vena caval filter placement, 123, 124
 pathogenesis
 chemotherapy and hormonal therapy, 113
 environmental factors, 113
 hematopoietic growth factors, 114, 115
 host-specific factors, 112
 proinflammatory cytokines production, 112
 thrombotic complications, 114
 tissue factor expression, 111, 112
 prevention
 contraindications, 116, 117
 medical oncology patients, 118
 pharmacologic and mechanical prophylaxis,
 115–118
 risk factors, 116
 recurrent VTE management
 anatomic vascular compression, 129
 heparin-induced thrombocytopenia (HIT), 128
 subtherapeutic anticoagulation, 127, 128
 Trousseau's syndrome, 128, 129
- Vitamin K antagonists (VKA), 124, 125
- W**
- Warfarin, 119, 126
- World Health Organization (WHO), 197